Current ENABLE-2 projects

ENABLE-2 has launched with five promising projects in the pursuit of new antibiotics. Currently, one each from Linköping University and biotech companies QureTech Bio AB and Thioredoxin Systems AB are selected for development together with two projects from Uppsala University.

ENABLE-2 projekt


A first-in-class antibiotic for treating multidrug-resistant bacteria
Resident at  Dep of Physics, Chemistry and Biology (IFM), Linköping University.

Frank Hernandez, Group leaderFrank Hernandez, Group leader
Nucleic Acids Technologies Lab (NAT-Lab)


A new class of antibacterial compounds against gram-positive bacteria & a well-developed chemistry platform to improve these new compounds
Resident at  QureTech Bio AB, Umeå

​Fredrik Almqvist, Research DirectorFredrik Almqvist, Research Director
QureTech Bio AB

Helen Fält, CEOHelén Fält, CEO
QureTech Bio AB


A novel chemical class with promising properties for continued development
Resident at  Preparative Medicinal ChemistryDep of Medicinal Chemistry, Uppsala University

Luke Odell, Associate ProfessorLuke Odell, Associate Professor
Uppsala University


A novel target with no preexisting resistance and a new compound class showing very good efficacy in animal models
Resident at  Drug Design and DiscoveryDep of Medicinal Chemistry & Dep of Medical Biochemistry and Microbiology, Uppsala University

Diarmaid Hughes, ProfessorDiarmaid Hughes, Professor
Uppsala University

Anders KarlenAnders Karlén, Professor
Uppsala University


A novel class of antibiotic active against multidrug-resistant gram-positive as well as gram-negative bacteria
Resident at  Thioredoxin Systems AB, Solna

Elias ArnérElias Arnér, MD PhD, Board Member, Scientific Advisor
Thioredoxin Systems AB
+46 70 556 96 94,

Mohamad TakwaMohamad Takwa, PhD, Board Member, CEO
Thioredoxin Systems AB
+46 72-322 22 21,

What ENABLE-2 can do for you

Apply to join


Susanna Thörnqvist, Project Coordinator
Uppsala University

Last modified: 2022-09-20